TY - JOUR
T1 - Overview of in-hospital outcomes in patients undergoing percutaneous coronary intervention with the revived directional coronary atherectomy
AU - J-PCI Registry Investigators
AU - Numasawa, Yohei
AU - Inohara, Taku
AU - Ishii, Hideki
AU - Yamaji, Kyohei
AU - Kohsaka, Shun
AU - Sawano, Mitsuaki
AU - Amano, Tetsuya
AU - Nakamura, Masato
AU - Ikari, Yuji
N1 - Funding Information:
The authors appreciate the contributions of all the investigators and staff involved in the J-PCI registry. The authors also thank Angela Morben, DVM, ELS, from Edanz (https://jp.edanz.com/ac), for editing a draft of this manuscript. This study was supported by the Japanese Association of Cardiovascular Intervention and Therapeutics (CVIT). Dr. Inohara received a research grant from Boston Scientific. Dr. Ishii received lecture fees from Astellas Pharma, AstraZeneca, Bayer, Bristol-Myers Squibb, Chugai Pharma, Daiichi Sankyo, and Otsuka Pharma. Dr. Kohsaka received investigator-initiated grant funding from Bayer and Daiichi Sankyo and personal fees from Bayer and Bristol-Myers Squibb. Dr. Sawano received lecture fees from Nippon Boehringer Ingelheim, Bristol-Myers Squibb, and Astellas Pharma, and investigator-initiated grant funding from Takeda Pharmaceutical. Dr. Amano received lecture fees from Astellas Pharma, AstraZeneca, Bayer, Daiichi Sankyo, and Bristol-Myers Squibb. Dr. Nakamura received remuneration for lectures from Daiichi Sankyo, Sanofi, Bayer, Nippon Boehringer Ingelheim, Bristol-Myers Squibb, Terumo, Japan Lifeline, Abbott, Boston Scientific, Medtronic, and Nipro, and investigator-initiated grant funding from Sanofi and Daiichi Sankyo. The remaining authors have no disclosures to report.
Funding Information:
The authors appreciate the contributions of all the investigators and staff involved in the J‐PCI registry. The authors also thank Angela Morben, DVM, ELS, from Edanz ( https://jp.edanz.com/ac ), for editing a draft of this manuscript. This study was supported by the Japanese Association of Cardiovascular Intervention and Therapeutics (CVIT). Dr. Inohara received a research grant from Boston Scientific. Dr. Ishii received lecture fees from Astellas Pharma, AstraZeneca, Bayer, Bristol‐Myers Squibb, Chugai Pharma, Daiichi Sankyo, and Otsuka Pharma. Dr. Kohsaka received investigator‐initiated grant funding from Bayer and Daiichi Sankyo and personal fees from Bayer and Bristol‐Myers Squibb. Dr. Sawano received lecture fees from Nippon Boehringer Ingelheim, Bristol‐Myers Squibb, and Astellas Pharma, and investigator‐initiated grant funding from Takeda Pharmaceutical. Dr. Amano received lecture fees from Astellas Pharma, AstraZeneca, Bayer, Daiichi Sankyo, and Bristol‐Myers Squibb. Dr. Nakamura received remuneration for lectures from Daiichi Sankyo, Sanofi, Bayer, Nippon Boehringer Ingelheim, Bristol‐Myers Squibb, Terumo, Japan Lifeline, Abbott, Boston Scientific, Medtronic, and Nipro, and investigator‐initiated grant funding from Sanofi and Daiichi Sankyo. The remaining authors have no disclosures to report.
Publisher Copyright:
© 2022 Wiley Periodicals LLC.
PY - 2022/7/1
Y1 - 2022/7/1
N2 - Objectives: We sought to provide clinical insights on the usage rate, indications, and in-hospital outcomes of the revived directional coronary atherectomy (DCA) catheter (Atherocut™) in a Japanese nationwide percutaneous coronary intervention (PCI) registry. Background: Debulking devices such as the revived DCA catheter have become increasingly important in the era of complex PCI. However, little is known about PCI outcomes using a novel DCA catheter in contemporary real-world practice. Methods: We analyzed 188,324 patients who underwent PCI in 1112 hospitals from January to December 2018. Baseline characteristics and in-hospital outcomes of patients with stable coronary artery disease or unstable angina who underwent PCI with or without the DCA were analyzed. Results: Overall, 1696 patients (0.9%) underwent PCI with the DCA during the study period, predominantly for left main trunk or proximal left anterior descending artery lesions under a transfemoral approach. Patients in the DCA group were younger and had fewer comorbidities such as hypertension, diabetes mellitus, and chronic kidney disease than patients in the non-DCA group. Stentless PCI using the DCA with drug-coated balloon angioplasty was a preferred treatment strategy in the DCA group (50.0%). Predefined in-hospital adverse outcomes, including mortality (0.2% vs. 0.3%, p = 0.446) and periprocedural complications (1.8% vs. 1.7%, p = 0.697), were comparable between the two groups, whereas the fluoroscopy time was longer and the total contrast volume was higher in the DCA group. Conclusions: In Japan, PCI using the revived DCA catheter is safely performed with low complication rates in patients with stable coronary artery disease or unstable angina.
AB - Objectives: We sought to provide clinical insights on the usage rate, indications, and in-hospital outcomes of the revived directional coronary atherectomy (DCA) catheter (Atherocut™) in a Japanese nationwide percutaneous coronary intervention (PCI) registry. Background: Debulking devices such as the revived DCA catheter have become increasingly important in the era of complex PCI. However, little is known about PCI outcomes using a novel DCA catheter in contemporary real-world practice. Methods: We analyzed 188,324 patients who underwent PCI in 1112 hospitals from January to December 2018. Baseline characteristics and in-hospital outcomes of patients with stable coronary artery disease or unstable angina who underwent PCI with or without the DCA were analyzed. Results: Overall, 1696 patients (0.9%) underwent PCI with the DCA during the study period, predominantly for left main trunk or proximal left anterior descending artery lesions under a transfemoral approach. Patients in the DCA group were younger and had fewer comorbidities such as hypertension, diabetes mellitus, and chronic kidney disease than patients in the non-DCA group. Stentless PCI using the DCA with drug-coated balloon angioplasty was a preferred treatment strategy in the DCA group (50.0%). Predefined in-hospital adverse outcomes, including mortality (0.2% vs. 0.3%, p = 0.446) and periprocedural complications (1.8% vs. 1.7%, p = 0.697), were comparable between the two groups, whereas the fluoroscopy time was longer and the total contrast volume was higher in the DCA group. Conclusions: In Japan, PCI using the revived DCA catheter is safely performed with low complication rates in patients with stable coronary artery disease or unstable angina.
KW - coronary artery disease
KW - directional coronary atherectomy
KW - drug-coated balloon
KW - percutaneous coronary intervention
UR - http://www.scopus.com/inward/record.url?scp=85131900973&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85131900973&partnerID=8YFLogxK
U2 - 10.1002/ccd.30233
DO - 10.1002/ccd.30233
M3 - Article
C2 - 35592940
AN - SCOPUS:85131900973
SN - 1522-1946
VL - 100
SP - 51
EP - 58
JO - Catheterization and Cardiovascular Interventions
JF - Catheterization and Cardiovascular Interventions
IS - 1
ER -